Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia

被引：0
|
作者：
Huetter, Marie-Luise [1 ]
Fiedler, Walter [2 ]
Kuendgen, Andrea [3 ]
Krauter, Juergen [4 ]
von Lilienfeld-Toal, Marie [5 ]
Kayser, Sabine [1 ]
Rafler, Heidi [1 ]
Doehner, Hartmut [1 ]
Schlenk, Richard F. [1 ]
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Univ Hosp Eppendorf, Hamburg, Germany
[3] Univ Hosp Dusseldorf, Dept Hematol & Oncol, Dusseldorf, Germany
[4] Hannover Med Sch, Klin Hamostasiol Onkol & Stammzelltransplant, D-30623 Hannover, Germany
[5] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1350 / 1351
页数：2
相关论文
共 50 条
  • [1] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    [J]. PANCREAS, 2017, 46 (03) : 437 - 437
  • [3] An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
    Fiedler, Walter
    Mesters, Rolf
    Heuser, Michael
    Ehninger, Gerhard
    Berdel, Wolfgang E.
    Zirrgiebel, Ute
    Robertson, Jane D.
    Puchalski, Tom A.
    Collins, Barbara
    Juergensmeier, Juliane M.
    Serve, Hubert
    [J]. LEUKEMIA RESEARCH, 2010, 34 (02) : 196 - 202
  • [4] An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma
    Abou-Alfa, G. K.
    Yoon, J. H.
    Modiano, M.
    Ryoo, B. Y.
    Yau, T.
    Freilich, B.
    Knox, J.
    Ly, M.
    Ahmed, H.
    Gahir, S.
    Niforos, D.
    Kowalski, M.
    Kelley, R. K.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S22 - S22
  • [5] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
    Li, Jun
    Han, Qi
    Huang, Yanqing
    Wei, Yanhui
    Zi, Jie
    Zhao, Lidong
    Cai, Zhimei
    Lu, Xuzhang
    Xiao, Rong
    Zhang, Yanming
    Yang, Xiaotian
    Xu, Hao
    Sun, Naitong
    Zhuang, Wanchuan
    Wu, Zhengdong
    Xia, Yuan
    Xu, Yanli
    He, Bin
    Zhu, Wei
    Min, Fengling
    Chen, Yongchun
    Ding, Banghe
    Shi, Peimin
    Xie, Jing
    Tang, Hua
    Liu, Zefa
    Li, Bingzong
    Sun, Yu
    Qiu, Hongxia
    Duan, Limin
    Dovat, Elanora
    Song, Chunhua
    SzeKely, Laszlo
    Dovat, Sinisa
    Ge, Zheng
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (10)
  • [6] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
    Jun Li
    Qi Han
    Yanqing Huang
    Yanhui Wei
    Jie Zi
    Lidong Zhao
    Zhimei Cai
    Xuzhang Lu
    Rong Xiao
    Yanming Zhang
    Xiaotian Yang
    Hao Xu
    Naitong Sun
    Wanchuan Zhuang
    Zhengdong Wu
    Yuan Xia
    Yanli Xu
    Bin He
    Wei Zhu
    Fengling Min
    Yongchun Chen
    Banghe Ding
    Peimin Shi
    Jing Xie
    Hua Tang
    Zefa Liu
    Bingzong Li
    Yu Sun
    Hongxia Qiu
    Limin Duan
    Elanora Dovat
    Chunhua Song
    Laszlo SzeKely
    Sinisa Dovat
    Zheng Ge
    [J]. Blood Cancer Journal, 12
  • [7] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [8] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Attar, Eyal C.
    Amrein, Philip C.
    Fraser, James W.
    Fathi, Amir T.
    McAfee, Steven
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Stone, Richard M.
    Foster, Julia
    Neuberg, Donna
    Ballen, Karen K.
    [J]. LEUKEMIA RESEARCH, 2013, 37 (09) : 1016 - 1020
  • [9] Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Amrein, Philip C.
    Attar, Eyal C.
    Fathi, Amir Tahmasb
    McAfee, Steven L.
    Wadleigh, Martha
    DeAngelo, Daniel J.
    Steensma, David P.
    Foster, Julia
    Stone, Richard M.
    Neuberg, Donna S.
    Ballen, Karen K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL-001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic-Lymphocytic-Leukemia
    Wendtner, Clemens M.
    Mahadevan, Daruka
    Stilgenbauer, Stephan
    Frankfurt, Olga
    Bloor, Adrian
    Bosch, Francesc
    Uharek, Lutz
    Furman, Richard R.
    Gobbi, Marco
    Gribben, John G.
    Kimby, Eva K.
    Sekeres, Mikkael A.
    Cripe, Larry D.
    Lombardy, Elyane
    Shah, Sheetal
    Moutouh-de Parseval, Laure A.
    Chanan-Khan, Asher Alban
    Knight, Robert D.
    [J]. BLOOD, 2008, 112 (11) : 732 - 732
12345